backgroundth
inflammatori
chemokin
interferongamma
induc
protein
kda
biomark
associ
sever
condit
objectivesthi
studi
investig
serum
concentr
healthi
individu
develop
acut
respiratori
infect
ari
hypothesi
serum
concentr
correl
ari
sever
detect
viral
pathogen
studi
designdata
come
random
control
trial
measur
effect
mind
medit
exercis
ari
clinic
trial
id
healthi
adult
age
follow
singl
season
ari
incid
sever
trial
ongo
investig
still
blind
particip
report
ari
symptom
nasal
swab
lavag
pcrbase
viral
identif
blood
sampl
collect
within
first
hour
ari
symptom
serum
concentr
measur
elisa
r
system
inc
quantikin
elisa
minneapoli
mn
ari
sever
measur
use
valid
wisconsin
upper
respiratori
symptom
survey
ari
episod
resolv
concentr
ari
episod
correl
ari
global
sever
rho
ci
p
concentr
higher
ari
viral
pathogen
detect
compar
viral
pathogen
detect
median
pgml
iqr
vs
pgml
iqr
p
influenza
infect
higher
concentr
coronaviru
enteroviru
rhinoviru
paramyxoviru
conclusionserum
concentr
correl
ari
global
sever
also
concentr
measur
earli
cours
ari
correl
daili
sever
durat
ill
symptom
inflammatori
chemokin
interferongamma
induc
protein
kda
also
known
cxc
motif
chemokin
ligand
biomark
associ
obes
insulin
resist
atherosclerosi
paraneoplast
neurolog
disord
infect
ligand
chemokin
cxc
motif
receptor
found
lymphocyt
natur
killer
nk
cell
eosinophil
encod
gene
chromosom
band
secret
monocyt
endotheli
cell
adipos
tissu
fibroblast
play
role
angiogenesi
inhibit
cell
chemotaxi
regul
cell
growth
prolifer
apoptosi
infect
associ
includ
caus
parasit
virus
bacteria
fungi
product
associ
protect
facilit
infect
recent
report
indic
increas
level
occur
acut
respiratori
infect
ari
suggest
biomark
role
present
studi
investig
serum
concentr
otherwis
healthi
patient
develop
ari
order
ascertain
link
ari
concentr
develop
biomark
virallymedi
ari
could
potenti
lead
methodolog
point
infect
etiolog
sever
order
formul
treatment
plan
base
previou
studi
hypothesi
serum
concentr
correl
ari
sever
durat
otherwis
healthi
individu
also
consid
detect
viru
nasal
specimen
would
associ
concentr
obtain
earli
ari
cours
could
potenti
help
clinic
use
marker
mild
moder
sever
acut
respiratori
infect
data
come
random
control
trial
measur
effect
mind
medit
exercis
incid
sever
ari
clinic
trial
id
studi
particip
communityrecruit
adult
age
gener
healthi
report
get
least
one
cold
per
year
three
cohort
healthi
individu
gave
written
inform
consent
three
season
enrol
august
septemb
follow
may
trial
ongo
investig
still
blind
concentr
use
analysi
measur
studi
entri
random
intervent
occur
within
first
hour
follow
onset
ari
still
unknown
medit
exercis
intervent
could
influenc
measur
studi
protocol
approv
univers
wisconsinmadison
institut
review
board
human
subject
research
particip
blood
drawn
studi
entri
particip
report
ari
symptom
equal
greater
jackson
scale
sampl
collect
within
first
hour
onset
symptom
blood
sampl
collect
use
standard
venipunctur
techniqu
serum
frozen
concentr
measur
picogram
per
millilit
pgml
use
elisa
accord
manufactur
protocol
r
system
minneapoli
mn
assay
rang
pgml
sampl
concentr
greater
highest
standard
dilut
direct
manufactur
protocol
remeasur
time
particip
contact
studi
coordin
report
ari
particip
perform
nasal
selfswab
nasal
lavag
done
time
blood
draw
multiplex
pcr
use
detect
identifi
respiratori
virus
nasal
swab
wash
sampl
rhinoviru
serotyp
well
serotyp
influenza
parainfluenza
coronaviru
respiratori
syncyti
viru
adenoviru
enteroviru
metapneumoviru
identifi
overal
sensit
estim
specif
virus
detect
either
nasal
swab
lavag
consid
posit
virus
group
type
analysi
adenoviru
bocaviru
coronavirus
enteroviru
rhinoviru
influenza
virus
paramyxovirus
metapneumoviru
parainfluenza
virus
respiratori
syncyti
virus
provid
written
inform
consent
particip
contact
everi
week
use
webbas
surveil
system
prompt
selfreport
ari
episod
jackson
criteria
use
defin
begin
ari
episod
three
criteria
met
answer
ye
either
think
cold
think
come
cold
report
least
one
four
cold
symptom
nasal
discharg
nasal
obstruct
sneez
sore
throat
score
least
two
point
jackson
scale
jackson
score
calcul
sum
score
eight
symptom
sneez
headach
malais
chilli
nasal
discharg
nasal
obstruct
sore
throat
cough
symptom
rate
absent
sever
data
symptom
sever
qualiti
life
impact
collect
daili
use
valid
wisconsin
upper
respiratori
symptom
survey
ari
episod
resolv
daili
sever
score
calcul
ad
wurss
item
day
calcul
area
curv
wurss
auc
ari
global
sever
sum
wurss
total
across
daili
time
point
ill
episod
use
trapezoid
approxim
appli
wurss
divid
three
categori
symptom
nasal
throat
qualiti
life
qol
symptom
assess
relationship
ari
ill
outcom
spearman
correl
comput
fisher
z
transform
use
comput
confid
interv
ci
around
correl
wilcoxon
score
comput
use
kruskalw
test
compar
continu
variabl
group
eg
ari
global
sever
particip
correspond
measur
versu
without
measur
time
ari
gener
linear
regress
model
techniqu
use
assess
relationship
ari
outcom
adjust
baselin
covari
age
sex
bodi
mass
index
bmi
repeat
measur
model
use
account
correl
observ
within
particip
one
ari
gener
linear
regress
model
techniqu
repeat
measur
correl
also
use
comput
lsmean
comparison
viral
infect
categori
use
tukey
adjust
multipl
comparison
ari
global
sever
ari
durat
highli
skew
measur
transform
measur
log
scale
run
regress
model
observ
measur
data
present
median
interquartil
rang
iqr
chang
baselin
model
log
base
transform
outcom
variabl
chang
calcul
ari
later
time
point
ari
baselin
beta
interpret
percentag
chang
outcom
eg
ari
global
sever
everi
unit
increas
predictor
variabl
eg
statist
analys
run
use
sa
individu
enrol
studi
particip
experienc
ari
episod
unabl
measur
level
ari
episod
due
challeng
get
sampl
within
hour
onset
symptom
requir
protocol
figur
thu
abl
collect
serum
sampl
concentr
ari
episod
occur
individu
tabl
characterist
ari
episod
correspond
collect
also
found
tabl
statist
signific
differ
ari
global
sever
ari
durat
ari
episod
collect
compar
ari
episod
collect
addit
unabl
collect
day
wurss
symptom
score
five
ari
day
symptom
level
analys
serum
baselin
correl
age
confid
interv
ci
p
bmi
ci
p
men
lower
women
baselin
vs
respect
differ
statist
signific
serum
correl
ari
sever
durat
symptom
figur
ari
induc
increas
baselin
almost
time
serum
increas
baselin
median
pgml
ari
median
pgml
p
baselin
correl
ari
outcom
ari
chang
correl
ari
outcom
tabl
ari
correl
significantli
ari
global
sever
ci
p
durat
ci
figur
adjust
age
sex
bmi
everi
unit
increas
logbas
increas
log
ari
global
sever
ci
tabl
impli
concentr
pgml
predict
unit
ci
unit
increas
ari
global
sever
everi
increas
baselin
increas
ari
global
sever
ci
ari
correl
ari
sever
day
serum
collect
expect
posit
direct
daili
sever
score
tabl
relationship
remain
adjust
age
gender
bmi
tabl
final
serum
concentr
higher
individu
ari
viral
pathogen
detect
pgml
compar
pathogen
identifi
nasal
specimen
pgml
p
paper
present
evid
concentr
earli
ari
may
serv
use
predictor
ari
outcom
includ
sever
durat
healthi
adult
concentr
appear
correl
symptom
sever
henc
could
serv
use
marker
predictor
ari
ill
sever
correl
symptom
day
measur
appear
predict
subsequ
sever
durat
appear
correl
three
group
symptom
use
measur
ari
sever
expect
potenti
biomark
serum
context
clinic
studi
one
report
particip
also
baselin
concentr
measur
studi
entri
time
sick
show
chang
concentr
ari
baselin
also
correl
ari
sever
durat
find
confirm
concentr
increas
ari
ill
exampl
could
potenti
help
riskstratif
refin
differenti
diagnosi
even
possibl
clinic
decisionmak
whether
initi
antivir
treatment
futur
work
would
need
formal
test
possibl
serum
correl
detect
viru
nasal
specimen
obtain
within
first
hour
symptom
parallel
correl
exist
influenza
paramyxoviru
infect
associ
higher
concentr
greater
ari
sever
measur
wurss
auc
compar
infect
caus
coronavirus
enterovirus
rhinovirus
result
consist
find
anoth
laboratori
found
higher
concentr
bronchoalveolar
lavag
sampl
viru
identifi
howev
patient
studi
much
sicker
hospit
underw
bronchoscopi
diagnosi
lower
respiratori
tract
infect
serum
biomark
ari
identifi
fact
allcaus
communityacquir
ari
ill
reliabl
predictor
sever
durat
exist
group
previous
found
posit
correl
concentr
nasal
wash
sever
durat
ari
nasal
symptom
includ
runni
nose
plug
nose
sneez
contrast
serum
procalcitonin
use
marker
ari
research
group
report
nasal
correl
ari
primarili
among
peopl
underli
ill
ari
caus
parainfluenza
viru
adult
sever
multipl
disabl
almost
fold
increas
serum
concentr
acut
phase
infect
addit
popul
underli
ill
asthma
copd
concentr
measur
serum
nasal
sampl
gene
express
correl
acut
respiratori
infect
lead
exacerb
although
concentr
higher
smoker
copd
smoker
gener
number
smoker
cohort
small
henc
unlik
influenc
concentr
howev
also
analyz
chang
ari
got
result
although
correl
rel
modest
studi
result
show
serum
potenti
use
marker
ari
sever
trend
ari
durat
healthi
popul
although
elev
influenza
infect
compar
control
shown
use
identifi
sever
influenza
infect
although
larg
increas
concentr
observ
parainfluenza
infect
correl
clinic
sever
infect
appar
contrast
found
concentr
correl
ari
symptom
day
measur
earli
cours
infect
well
sever
durat
ari
cohort
healthi
individu
ari
episod
healthi
individu
mild
moder
sever
communityrecruit
femalepredomin
particip
primarili
white
welleduc
agre
monitor
coldandflu
season
vast
major
ill
episod
sever
enough
prompt
clinic
evalu
sampl
collect
peopl
present
clinic
would
like
demonstr
somewhat
higher
sever
biomark
valu
might
influenc
relationship
report
nasal
specimen
viru
detect
certainli
alway
without
viral
infecti
caus
sever
reason
identifi
viru
someon
sick
appear
ari
test
viru
caus
infect
symptom
associ
allerg
respons
inflammatori
reaction
infect
bacteri
fungal
etiolog
symptom
caus
chemic
irrit
symptom
psychosomat
studi
result
provid
evid
biomark
ari
sever
healthi
adult
serum
concentr
correl
ari
sever
measur
wurss
day
measur
also
concentr
measur
earli
cours
ari
correl
sever
trend
durat
ill
serum
concentr
ari
episod
correl
ari
sever
day
measur
overal
ari
sever
episod
concentr
higher
ari
viral
pathogen
detect
compar
viral
pathogen
detect
influenza
infect
induc
higher
concentr
coronaviru
enteroviru
rhinoviru
paramyxoviru
may
biomark
ari
sever
presenc
viral
pathogen
model
use
logbas
transform
model
includ
follow
covari
age
gender
bmi
baselin
observ
day
blood
draw
